Screening of Wound-Healing Agents

Screening of Wound-Healing Agents

1. Definition, rationale & the biology being modelled

• Wound healing is defined experimentally as a multiphasic reparative process whose progress can be quantified by measuring the mechanical strength developed at the wound site at various time intervals after injury; the effect of a candidate drug is inferred from how it shifts these time-course parameters against controls (Vogel 4e, V4 Part XVII, Healing of Skin Wounds, p.3981).
• Screening of wound-healing agents = the battery of standardised in vivo (rat/mouse) and in vitro assays used to detect and rank pro-healing (or anti-healing) activity of a test substance — herbal extract, growth factor, dressing, or drug — against a validated reference standard.
• The reparative sequence being modelled has overlapping phases, each supplying a distinct measurable endpoint:
  • Haemostasis — clot/platelet plug, provisional fibrin matrix (immediate).
  • Inflammatory phase — transient local vasodilatation, increased capillary permeability, and infiltration of leukocytes/phagocytes; PGE₂ and prostacyclin (PGI₂) are the primary prostanoids that mediate this phase, alongside histamine, bradykinin, 5-HT, LTs, PAF and cytokines (TNF, IL-1) (G&G 14e Ch.42, pp. inflammation intro).
  • Proliferative phase — fibroblast proliferation, angiogenesis (new-vessel formation), granulation-tissue deposition, collagen synthesis, and re-epithelialisation (keratinocyte migration).
  • Remodelling/maturation phase — collagen cross-linking and reorganisation, giving progressive gain in tensile (breaking) strength (Vogel 4e, V4 Part XVII, p.3981; correlation of strength with insoluble collagen, p.3975).
• Because different phases dominate at different times, no single model captures all of healing — the classic screen therefore runs three complementary rat models in parallel: excision (contraction + epithelialisation), incision (tensile/breaking strength), and dead-space (granulation-tissue collagen/hydroxyproline). Special models (burn, diabetic/steroid-impaired) probe healing under adverse conditions.
• In-vitro correlates (scratch/migration assay, angiogenesis assays) isolate single cellular events (keratinocyte/fibroblast/endothelial migration) for mechanistic and high-throughput screening.

Why prostanoids and steroids matter to the screen (pharmacological rationale):

• Prostanoid biosynthesis is markedly increased in inflamed/injured tissue; PGE₂ and PGI₂ raise local blood flow and vascular permeability and orchestrate the early inflammatory phase (G&G 14e Ch.42). NSAIDs (COX inhibitors) and glucocorticoids therefore modulate healing — this is exactly why anti-inflammatory drugs are the canonical positive (accelerating) or negative (impairing) control compounds in a wound-healing screen.
• Vogel documents a dose-dependent increase of skin tensile strength after NSAIDs (Vogel 1977) and a characteristic biphasic corticosteroid effect — see §7 (Vogel 4e, V4 Part XVII, p.3964).